1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
62D1FEE7F327265EF652580C600252FC7
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-best-practices-scientific-publications-strategy-best-practices-lessons-learned?opendocument
18
19opendocument
2034.226.234.20
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Scientific Publications

Best Practices in Scientific Publications Strategy: Neutral/Negative Results and Publication Best Practices

ID: 5450


Features:

13 Info Graphics

8 Data Graphics

80+ Metrics

8 Narratives

18 Best Practices


Pages/Slides: 34


Published: 2017


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from Best Practices in Scientific Publications Strategy: Neutral/Negative Results and Publication Best Practices”

STUDY OVERVIEW

Global scientific publications function at bio-pharmaceutical companies face increasing calls for improved transparency and data disclosure. Consequently, global publications leaders find themselves in a balancing act - ensuring both scientific credibility and commercial feasibility.

Best Practices, LLC undertook benchmarking research to explore how leading bio-pharmaceutical companies shape their global scientific publication strategies and plans to maintain credibility in the scientific community and drive commercial success. In particular, this study identifies publication strategy changes for the new marketplace, best practices for maximizing the effectiveness of strategic publication planning, top publication challenges and lessons learned for implementing successful scientific publication strategy.

KEY TOPICS

  • Tactics for Handling Publication of Neutral or Negative Clinical Trial Results
  • Future Publishing Emphasis
  • Strategy Changes for the New Marketplace
  • Best Practices for Maximizing the Effectiveness of Strategic Publication Planning
  • Top Publication Challenges
  • Lessons Learned for Implementing Successful Scientific Publication Strategy

KEY METRICS

  • Use of Scenario Planning for Publishing Neutral/Negative Clinical Trial Results
  • How Will Journal Emphasis Change over Next Three Years to Provide Greater Transparency
  • Changes Made to Maintain Publication Excellence
  • Best Practices for Maximizing the Effectiveness of Medical / Scientific Strategic Publication Planning
  • Top Medical Publication Challenges over the Next 1-3 Years
  • Most Important Lessons Learned for Implementing Successful Scientific Publication Strategy

SAMPLE KEY FINDINGS

  • Companies Use Scenario Planning for Publishing Neutral/Negative Clinical Trial Results: Two-thirds of companies use scenario planning as part of their strategy for publishing neutral and/or negative results. When building these scenarios, publication groups consider the content to be published, the timing for publication and the channel used for publication. Participants – and the industry in general - publish all data irrespective of the results within 1-1.5 years; however, the journal criteria is changed and lower-impact journals are used for publication.

METHODOLOGY


Best Practices, LLC engaged 20 leaders from 19 leading bio-pharmaceutical companies with direct experience working in scientific publishing. Almost 75% of participants are from the U.S. region.


Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Chemical; Health Care; Research; Distribution; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Alexion Pharmaceuticals; AstraZeneca; Bayer; Biotronik; Bioventus; Celgene; Genentech; Karyopharm Therapeutics; KimberlyClark; Lonza Inc.; McKessonHBOC; Nobel Biocare; Novartis; Portola Pharmaceuticals; Roche; Sanofi; Sirtex; Teva Pharmaceutical Industries Ltd; UCB Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.